160 related articles for article (PubMed ID: 37145099)
1. Inhibition of nonsense-mediated mRNA decay may improve stop codon read-through therapy for Duchenne muscular dystrophy.
Amar-Schwartz A; Cohen Y; Elhaj A; Ben-Hur V; Siegfried Z; Karni R; Dor T
Hum Mol Genet; 2023 Jul; 32(15):2455-2463. PubMed ID: 37145099
[TBL] [Abstract][Full Text] [Related]
2. A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy.
Kimura S; Ito K; Miyagi T; Hiranuma T; Yoshioka K; Ozasa S; Matsukura M; Ikezawa M; Matsuo M; Takeshima Y; Miike T
Brain Dev; 2005 Sep; 27(6):400-5. PubMed ID: 16122626
[TBL] [Abstract][Full Text] [Related]
3. Premature termination codons in the
García-Rodríguez R; Hiller M; Jiménez-Gracia L; van der Pal Z; Balog J; Adamzek K; Aartsma-Rus A; Spitali P
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16456-16464. PubMed ID: 32616572
[TBL] [Abstract][Full Text] [Related]
4. Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.
Flanigan KM; Dunn DM; von Niederhausern A; Soltanzadeh P; Howard MT; Sampson JB; Swoboda KJ; Bromberg MB; Mendell JR; Taylor LE; Anderson CB; Pestronk A; Florence JM; Connolly AM; Mathews KD; Wong B; Finkel RS; Bonnemann CG; Day JW; McDonald C; ; Weiss RB
Hum Mutat; 2011 Mar; 32(3):299-308. PubMed ID: 21972111
[TBL] [Abstract][Full Text] [Related]
5. The position of nonsense mutations can predict the phenotype severity: A survey on the DMD gene.
Torella A; Zanobio M; Zeuli R; Del Vecchio Blanco F; Savarese M; Giugliano T; Garofalo A; Piluso G; Politano L; Nigro V
PLoS One; 2020; 15(8):e0237803. PubMed ID: 32813700
[TBL] [Abstract][Full Text] [Related]
6. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
7. Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy.
Okubo M; Noguchi S; Hayashi S; Nakamura H; Komaki H; Matsuo M; Nishino I
Hum Genet; 2020 Feb; 139(2):247-255. PubMed ID: 31919629
[TBL] [Abstract][Full Text] [Related]
8. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations.
Wagner KR; Hamed S; Hadley DW; Gropman AL; Burstein AH; Escolar DM; Hoffman EP; Fischbeck KH
Ann Neurol; 2001 Jun; 49(6):706-11. PubMed ID: 11409421
[TBL] [Abstract][Full Text] [Related]
9. Read-through approach for stop mutations in Duchenne muscular dystrophy. An update.
Politano L
Acta Myol; 2021 Mar; 40(1):43-50. PubMed ID: 33870095
[TBL] [Abstract][Full Text] [Related]
10. Emerging genetic therapies to treat Duchenne muscular dystrophy.
Nelson SF; Crosbie RH; Miceli MC; Spencer MJ
Curr Opin Neurol; 2009 Oct; 22(5):532-8. PubMed ID: 19745732
[TBL] [Abstract][Full Text] [Related]
11. Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay?
Kerr TP; Sewry CA; Robb SA; Roberts RG
Hum Genet; 2001 Oct; 109(4):402-7. PubMed ID: 11702221
[TBL] [Abstract][Full Text] [Related]
12. Low-level dystrophin expression attenuating the dystrophinopathy phenotype.
Waldrop MA; Gumienny F; El Husayni S; Frank DE; Weiss RB; Flanigan KM
Neuromuscul Disord; 2018 Feb; 28(2):116-121. PubMed ID: 29305136
[TBL] [Abstract][Full Text] [Related]
13. Disease-proportional proteasomal degradation of missense dystrophins.
Talsness DM; Belanto JJ; Ervasti JM
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12414-9. PubMed ID: 26392559
[TBL] [Abstract][Full Text] [Related]
14. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
Takeshima Y
Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
[TBL] [Abstract][Full Text] [Related]
15. Next Generation Sequencing approach to molecular diagnosis of Duchenne muscular dystrophy; identification of a novel mutation.
Ebrahimzadeh-Vesal R; Teymoori A; Azimi-Nezhad M; Hosseini FS
Gene; 2018 Feb; 644():1-3. PubMed ID: 29246534
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing.
Magri F; Del Bo R; D'Angelo MG; Govoni A; Ghezzi S; Gandossini S; Sciacco M; Ciscato P; Bordoni A; Tedeschi S; Fortunato F; Lucchini V; Cereda M; Corti S; Moggio M; Bresolin N; Comi GP
BMC Med Genet; 2011 Mar; 12():37. PubMed ID: 21396098
[TBL] [Abstract][Full Text] [Related]
17. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.
Finkel RS; Flanigan KM; Wong B; Bönnemann C; Sampson J; Sweeney HL; Reha A; Northcutt VJ; Elfring G; Barth J; Peltz SW
PLoS One; 2013; 8(12):e81302. PubMed ID: 24349052
[TBL] [Abstract][Full Text] [Related]
18. DMD transcript imbalance determines dystrophin levels.
Spitali P; van den Bergen JC; Verhaart IE; Wokke B; Janson AA; van den Eijnde R; den Dunnen JT; Laros JF; Verschuuren JJ; 't Hoen PA; Aartsma-Rus A
FASEB J; 2013 Dec; 27(12):4909-16. PubMed ID: 23975932
[TBL] [Abstract][Full Text] [Related]
19. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
Finkel RS
J Child Neurol; 2010 Sep; 25(9):1158-64. PubMed ID: 20519671
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in Czech DMD/BMD patients and their phenotypic outcome.
Sedlácková J; Vondrácek P; Hermanová M; Zámecník J; Hrubá Z; Haberlová J; Kraus J; Maríková T; Hedvicáková P; Vohánka S; Fajkusová L
Neuromuscul Disord; 2009 Nov; 19(11):749-53. PubMed ID: 19783145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
